This prospective, open-label, single arm, non-interventional study will investigate the effectiveness of bevacizumab monotherapy in participants with lung adenocarcinoma who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab.

Inclusion Criteria:

• Participant who previously received 4 to 6 cycles of induction platinum doublet plus bevacizumab
• Participant who received only 1 cycle of bevacizumab maintenance treatment
• Meet summary of product characteristics guidelines

Exclusion Criteria:

• Participant who received the first cycle of maintenance bevacizumab more than 4 weeks after the postinduction tumor assessment
• Pregnant or breast-feeding

Patients receiving Avastin monotherapy as maintenance treatment